CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Adcetris for Hodgkin Lymphoma Resubmission – Details

Project Number PC0145-000
Brand Name Adcetris (Resubmission)
Generic Name Brentuximab Vedotin
Strength 50 mg
Tumour Type Lymphoma
Indication Hodgkin Lymphoma
Funding Request For the treatment of patients with HL after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates
Review Status Complete
Pre Noc Submission No
NOC Date February 1, 2013
Manufacturer Seattle Genetics, Inc.
Sponsor Seattle Genetics, Inc.
Submission Date August 27, 2018
Submission Deemed Complete September 11, 2018
Submission Type Resubmission
Prioritization Requested Requested and Granted
Stakeholder Input Deadline ‡ September 11, 2018
Check-point meeting October 23, 2018
pERC Meeting December 13, 2018
Initial Recommendation Issued January 4, 2019
Feedback Deadline ‡ January 18, 2019
pERC Reconsideration Meeting February 21, 2019
Final Recommendation Issued March 7, 2019
Notification to Implement Issued March 22, 2019
Therapeutic Area Hodgkin lymphoma (HL)
Recommendation Type Do not reimburse

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.